CD274 and neoplasm: When combined with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), this approach can amplify the local therapeutic effect and potentially induce systemic anti-tumor immunity, as evidenced by abscopal (distant) effects in preclinical models [51,52].